

THE ANTIBODY SERIES 2022

BRINGING TOGETHER EXPERTS TO DISCUSS INNOVATION IN ANTIBODY DISCOVERY AND DEVELOPMENT

Sept 7-8, 2022

SuperBock Arena
Porto, Portugal

Sept 6, 2022

All Day Pre-check in to the conference
19h30 Welcome Dinner at FairJourney Biologics

Sept 7, 2022

8h45 - 9h00 Welcome Address - Day 1
Ton Logtenberg
Chairman of The Antibody Series 2022

Session - The Blood Brain Barrier and Targeting Neurodegenerative Diseases

9h00 - 9h30 Brain Delivery of Therapeutic Proteins Using an Fc Fragment Blood-Brain Barrier Transport Vehicle



Joe Lewcock
CSO at Denali Therapeutics

9h30 - 10h00 Next Generation Vectorized Antibody Therapies for Neurodegenerative Diseases



Sander van Deventer
Founder and Chief Technology Officer at Vector Y B.V.

10h00 - 10h15 Panel Discussion
Joe Lewcock & Prof. Sander van Deventer

10h15 - 11h00 Coffee Break

Session - Affinity, Avidity and Novel Mechanisms of Action

11h00 - 11h30 Avidity Engineering of Antibodies



Paul W.H.I. Parren
Executive Vice President and Head of R&D Lava Therapeutics

11h30 - 12h00 Drug-like Antibodies by Design and Directed Evolution



Peter Tessier
Albert M. Mattocks (Endowed) Professor in the Departments of Chemical Engineering, Pharmaceutical Sciences and Biomedical Engineering

12h00 - 12h15 Panel Discussion
Prof. Paul W.H.I. Parren & Peter Tessier

12h15 - 13h15 Lunch Break

13h15 - 14h15 New Technology Developments for Future (Multispecific) Antibody Discovery and Optimization



Rene Hoet
Chief Innovation Officer at FairJourney Biologics

Session - Artificial Intelligence & Antibodies

14h15 - 14h45 Reimagining Therapeutic Antibodies Using Artificial Intelligence



Yanay Ofran
Founder & CEO of BioJicDesign

14h45 - 15h15 Transforming Immunology and Target Discovery Using Machine Learning



Aridaman Pandit
Senior Principal Research Scientist at Abbvie

15h15 - 15h30 Panel Discussion
Yanay Ofran & Aridaman Pandit

15h30 - 16h00 Coffee Break

Session - Antibody Discovery

16h00 - 16h30 Mining the Immune System for Protective Antibodies



Jane Osbourn
CSO at Alchemab Therapeutics Ltd

16h30 - 17h00 Trispecific Antibodies as the Next Generation of T cell Immunotherapy



Marta Amaral
Laboratory Head Engineered Antibodies and Protein Therapeutics at Sanofi

17h00 - 17h30 High Resolution Epitope Binning Informs Antibody Drug Discovery for Infectious Disease and Enhances Next Generation Antibody Workflows



Daniel Bedinger
Application Science Team Lead at Carterra

17h30 - 17h45 Panel Discussion & Closing
Jane Osbourn, Marta Amaral & Daniel Bedinger

20h00 Formal Dinner at The Barron's Hall

THE ANTIBODY SERIES 2022

BRINGING TOGETHER EXPERTS TO DISCUSS INNOVATION IN ANTIBODY DISCOVERY AND DEVELOPMENT

Sept 7-8, 2022

SuperBock Arena
Porto, Portugal

Sept 8, 2022

8h45 - 9h00

Welcome Address - Day 2

Ton Logtenberg

Chairman of The Antibody Series 2022

Session - Novel Mechanisms of Action

9h00 - 9h30

Enhancing Endogenous and Synthetic Immunity with Engineered Antibody-Fusion Proteins for Cancer Immunotherapy



Pablo Umaña

Roche Head Cancer Immunotherapy Discovery,
Roche Pharma Research and Early Development

9h30 - 10h00

Discovery of a Trispecific T cell Engager for Solid Tumors



John de Kruif

EVP & CTO at Merus NV

10h00 - 10h15

Panel Discussion

Pablo Umaña & John de Kruif

10h15 - 11h00

Coffee Break

11h00 - 11h30

The Two Sides of Targeting Checkpoint Receptors



Nathan Robertson

Head of Protein Engineering MiroBioHead
of Protein Engineering MiroBio

11h30 - 12h00

Multi specific antibodies



Fernando Garces

Director Protein Therapeutics at Gilead

12h00 - 12h15

Panel Discussion

Nathan Robertson & Fernando Garces

12h15 - 13h15

Lunch Break

13h15 - 13h45

FairJourney Biologics Presentation



Teresa Barata

Head of Protein Sciences Division at Flow Eighteen38

13h45 - 13h15

Stable Cell Line Development for Antibody Discovery and Production



António Barroso

Head of Cell Line Development at FairJourney Biologics

Session - Targeting the Tumor Micro-environment

14h15 - 14h45

Understanding Antibody Effector Function in the Context of Suppressive Tumour Microenvironments



Stephen Beers

PhD, Professor of Immunology and Immunotherapy,
Centre for Cancer Immunology, School of Cancer
Sciences University of Southampton

14h45 - 15h15

Inhibiting the Adenosine Pathway for Cancer Therapeutics



Horacio Natri

Associate Vice President, Biotherapeutics at Incyte

15h15 - 15h30

Panel Discussion

Stephen Beers & Horatio Natri

15h30 - 16h00

Coffee Break

16h00 - 16h30

Using the B-Body Bispecific Platform to Specifically Target and Eliminate Tumor-resident Tregs



Jonathan Davis

VP of Innovation and Strategy at Invenra

16h30 - 17h00

Closing & introduction to the next Chairman of The Antibody Series 2023

10th Year Anniversary Boat Trip

Sept 9, 2022

8h00 Meet at FairJourney Biologics Facilities

8h15 Departure for Douro

0h00 Estimated Arrival at Gaia Pier